# VNX-202

Source: https://onco.cc/drugs/vnx-202/  
OnCo record `vnx-202` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

VNX-202 is an experimental in vivo gene therapy: AAV vector encoding a bispecific T-cell engager from Vironexis Biotherapeutics, in phase 1 trials for HER2-expressing solid tumours.

## Summary

VNX-202 (AAV.CD3/HER2) is an in vivo gene therapy: AAV vector encoding a bispecific T-cell engager from Vironexis Biotherapeutics. A single intravenous dose of an adeno-associated virus vector encoding a CD3 x HER2 bispecific T-cell engager. Its furthest stage is phase 1, for HER2-expressing solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 NCT07192432 recruiting. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Also known as: AAV.CD3/HER2
- Tags: pipeline; ctgov-ingest
- Code: VNX-202
- Modality: In vivo gene therapy: AAV vector encoding a bispecific T-cell engager
- Mechanism: A single intravenous dose of an adeno-associated virus vector encoding a CD3 x HER2 bispecific T-cell engager.

## Sources

- Vironexis Biotherapeutics: vironexis.com: https://vironexis.com
- Vironexis Biotherapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07192432
- ClinicalTrials.gov: trials of VNX-202: https://clinicaltrials.gov/search?intr=VNX-202

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [CD3](https://onco.cc/targets/cd3/), [HER2](https://onco.cc/targets/her2/)
- companies: [Vironexis Biotherapeutics](https://onco.cc/companies/vironexis-biotherapeutics/)
- trials: [Gene Therapy for HER-Positive Cancer (SENTRY-HER2)](https://onco.cc/trials/nct07192432/)

---
JSON: https://onco.cc/api/v1/entities/vnx-202.json